| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Histone lysine demethylase MINA; MDIG; MINA; NO52; ROX; ;Ribosomal oxygenase 2 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human Ribosomal oxygenase 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于MINA53抗体的3篇参考文献的简要信息，涵盖其功能、作用机制及在疾病中的研究：
---
1. **文献名称**: *"Histone demethylation by a nuclear LSD1 homolog"*
**作者**: Tsukada Y, et al.
**摘要**: 该研究首次报道MINA53(又称NO52)作为核内依赖的组蛋白去甲基化酶，属于JmjC家族蛋白。实验通过特异性抗体验证其在HeLa细胞中的定位及对核糖体RNA的修饰作用，揭示了MINA53通过调控核糖体生物合成影响细胞增殖。
---
2. **文献名称**: *"Overexpression of MINA53 in colorectal cancer and its association with poor prognosis"*
**作者**: Fujiwara T, et al.
**摘要**: 研究利用MINA53抗体对结直肠癌组织进行免疫组化分析，发现MINA53在肿瘤组织中显著高表达，且与患者生存率负相关。机制研究表明其通过促进核糖体成熟驱动癌细胞增殖，提示其作为潜在治疗靶点。
---
3. **文献名称**: *"MINA53 interacts with p53 and regulates its transcriptional activity"*
**作者**: Linder B, et al.
**摘要**: 通过免疫共沉淀(使用MINA53抗体)和荧光共定位实验，证明MINA53与p53直接相互作用，抑制p53介导的凋亡基因表达。研究揭示了MINA53在DNA损伤应答中的新功能，为癌症耐药性提供了机制解释。
---
4. **文献名称**: *"The role of MINA53 in hypoxia-induced ribosomal stress"*
**作者**: Zhou X, et al.
**摘要**: 该研究利用MINA53敲低细胞系和特异性抗体检测，发现缺氧条件下MINA53通过维持核糖体稳定性缓解内质网应激，促进肿瘤细胞在低氧微环境中的存活，为靶向MINA53的抗癌策略提供依据。
---
以上文献均涉及MINA53抗体的实验应用(如Western blot、免疫组化、免疫沉淀等)，并围绕其酶活性、癌症关联及分子机制展开。如需具体期刊年份或页码，可进一步补充检索。
MINA53 antibody targets the MINA53 protein, a member of the JmjC domain-containing family implicated in ribosomal RNA (rRNA) processing and epigenetic regulation. MINA53. also known as MINA53 or NO52. is a 53 kDa protein encoded by the *MINA* gene in humans. It functions as a ribosomal oxygenase, utilizing iron and α-ketoglutarate to catalyze histone demethylation and hydroxylation of specific ribosomal proteins, thereby influencing ribosome biogenesis and translation efficiency. MINA53 is involved in cell proliferation, differentiation, and oncogenesis, with overexpression observed in cancers like hepatocellular carcinoma and colorectal cancer, correlating with poor prognosis.
Antibodies against MINA53 are essential tools for studying its expression, localization, and function. They are commonly used in techniques such as Western blotting, immunofluorescence (IF), and immunohistochemistry (IHC) to detect MINA53 in cell lines, tissues, or tumor samples. These antibodies aid in elucidating MINA53's role in linking metabolic pathways to epigenetic and translational regulation, particularly under hypoxic conditions or during oncogenic stress. Validated MINA53 antibodies typically recognize specific epitopes within its conserved JmjC or C-terminal domains, ensuring specificity. Researchers rely on these reagents to explore MINA53's potential as a therapeutic target or biomarker in cancer and other diseases linked to ribosomal dysfunction.
×
